ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.

Autor:	Li, P1, Fang, Y J1, Li, F2, Ou, Q J1, Chen, G1, Ma, G3
Zdroj:	British Journal of Cancer. 4/2/2013, Vol. 108 Issue 6, p1238-1244. 7p. 1 Color Photograph, 3 Charts, 2 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu